23:53 , Jun 22, 2016 |  BC Extra  |  Company News

Management tracks

Endocyte Inc. (NASDAQ:ECYT) said Ron Ellis resigned as president and CEO. The cancer company promoted CFO and COO Mike Sherman to succeed Ellis. Sherman will remain CFO. Bristol-Myers Squibb Co. (NYSE:BMY) promoted Murdo Gordon to...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

Alvine, Immunogenics deal

Immunogenics’ ImmunogenX subsidiary acquired Alvine’s non-cash assets, including latiglutenase and three celiac disease patient-reported outcome tools. Latiglutenase is a combination of a cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) engineered to degrade gluten...
02:48 , Dec 19, 2015 |  BC Extra  |  Company News

Management tracks

Medigene AG (Xetra:MDG1) named CSO Dolores Schendel CEO, effective Feb. 1. She will replace Frank Mathias. Vice Chairman Dave Lemus will become COO on Jan. 1. Anti-parasitic company Turing Pharmaceuticals AG (Zug, Switzerland) said CEO...
08:00 , Nov 4, 2013 |  BC Week In Review  |  Clinical News

ALV003: Phase IIb started

Alvine began the double-blind, placebo-controlled, dose-ranging, international Phase IIb CeliAction Study to evaluate oral ALV003 for 12 weeks in about 500 patients with celiac disease who are symptomatic despite attempting to follow a gluten-free diet....
07:00 , Oct 7, 2013 |  BioCentury  |  Strategy

Room for improvement

AbbVie Inc. has struck two deals for compounds that would compete with marketed products against the same targets, banking that partners Ablynx N.V. and Galapagos N.V. will be able to show their compounds produce better...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Alvine, AbbVie deal

Alvine granted AbbVie an exclusive option to acquire the company or its ALV003 , which is in Phase II testing to treat celiac disease, under undisclosed terms. AbbVie will pay Alvine $70 million up front...
00:39 , May 15, 2013 |  BC Extra  |  Company News

Alvine grants AbbVie option for celiac compound

Alvine Pharmaceuticals Inc. (San Carlos, Calif.) granted AbbVie Inc. (NYSE:ABBV) an exclusive option to acquire the company or its ALV003 , which is in Phase II testing to treat celiac disease, under undisclosed terms. AbbVie...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Clinical News

ALV003 regulatory update

FDA granted Fast Track designation for Alvine's ALV003 to treat celiac disease. The product is in Phase II testing for the indication. ALV003 is a combination of a cysteine protease (EP-B2) and a proline-specific prolyl...
07:00 , Mar 26, 2012 |  BioCentury  |  Emerging Company Profile

ImmusanT: Having their cake

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance....
07:00 , Oct 17, 2011 |  BC Week In Review  |  Clinical News

ALV003: Phase IIa data

A double-blind, Finnish Phase IIa trial in 34 evaluable patients showed that once-daily oral ALV003 met the primary endpoint of significantly less intestinal mucosal injury as measured by the change from baseline in intestinal villus...